home / stock / cerc / cerc short
Short Information | Cerecor Inc. (NASDAQ:CERC)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 969,298 |
Total Actual Volume | 7,471,709 |
Short Trends | |
---|---|
Cover Days | 20 |
Short Days | 0 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 48,465 |
Average Short Percentage | 12.83% |
Is there a CERC Short Squeeze or Breakout about to happen?
See the CERC Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
08-25-2021 | $2.98 | $2.93 | $2.98 | $2.9 | 266,862 | 18,954 | 7.1% |
08-24-2021 | $2.88 | $2.98 | $3 | $2.88 | 401,043 | 28,187 | 7.03% |
08-23-2021 | $2.82 | $2.89 | $2.93 | $2.7711 | 256,800 | 18,885 | 7.35% |
08-20-2021 | $2.62 | $2.77 | $2.83 | $2.62 | 376,450 | 56,071 | 14.89% |
08-19-2021 | $2.8 | $2.65 | $2.8893 | $2.61 | 419,575 | 72,789 | 17.35% |
08-18-2021 | $2.79 | $2.78 | $2.87 | $2.72 | 207,544 | 39,989 | 19.27% |
08-17-2021 | $2.73 | $2.79 | $2.81 | $2.6899 | 272,871 | 44,948 | 16.47% |
08-16-2021 | $2.84 | $2.77 | $2.87 | $2.66 | 421,880 | 62,443 | 14.8% |
08-12-2021 | $3.02 | $2.93 | $3.03 | $2.9 | 407,562 | 56,598 | 13.89% |
08-11-2021 | $2.96 | $3.06 | $3.06 | $2.88 | 472,972 | 74,974 | 15.85% |
08-10-2021 | $2.98 | $2.96 | $3.1 | $2.95 | 339,852 | 83,137 | 24.46% |
08-09-2021 | $2.88 | $3.02 | $3.05 | $2.8302 | 532,098 | 79,667 | 14.97% |
08-06-2021 | $2.82 | $2.82 | $2.89 | $2.74 | 472,857 | 91,649 | 19.38% |
08-05-2021 | $2.66 | $2.82 | $2.82 | $2.66 | 404,827 | 37,097 | 9.16% |
08-04-2021 | $2.67 | $2.68 | $2.76 | $2.61 | 537,893 | 44,909 | 8.35% |
08-03-2021 | $2.66 | $2.69 | $2.73 | $2.63 | 341,825 | 59,511 | 17.41% |
08-02-2021 | $2.66 | $2.69 | $2.7899 | $2.65 | 320,474 | 19,772 | 6.17% |
07-30-2021 | $2.68 | $2.66 | $2.72 | $2.64 | 351,724 | 45,013 | 12.8% |
07-29-2021 | $2.75 | $2.69 | $2.805 | $2.69 | 301,825 | 6,501 | 2.15% |
07-28-2021 | $2.72 | $2.75 | $2.845 | $2.68 | 364,775 | 28,204 | 7.73% |
News, Short Squeeze, Breakout and More Instantly...
Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent Directors Board of Director appointments in conjunction with Avalo’s recent acquisition of AVTX-009, an anti-IL-1β mAb, and up to $185 million private placement financ...
Acquired AVTX-009, Phase-2 ready anti-IL-1β mAb, in March 2024 Increased cash position with private placement financing in March 2024 providing up to $185 million, including initial upfront investment of $115.6 million Topline results from planned Phase 2 trial of AVTX-00...
Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026 Executed private placement financing of up to $185 million, including initial upfront invest...